These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 11362608)

  • 21. FDA triple header. Food and Drug Administration.
    Smart T
    GMHC Treat Issues; 1995 Nov; 9(11):1-3. PubMed ID: 11362986
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Conference highlight.
    J Int Assoc Physicians AIDS Care; 1995 Aug; 1(7):26. PubMed ID: 11362749
    [TBL] [Abstract][Full Text] [Related]  

  • 23. FDA approves 3TC and saquinavir. Food and Drug Administration.
    Baker R
    BETA; 1995 Dec; ():5, 9. PubMed ID: 11363011
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Saquinavir for treatment of patients with HIV.
    Am Fam Physician; 1996 Feb; 53(2):782, 785. PubMed ID: 8629551
    [No Abstract]   [Full Text] [Related]  

  • 25. Protease inhibitor trials moving to next phase.
    AIDS Alert; 1995 Aug; 10(8):100-1. PubMed ID: 11362675
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [The safety and efficacy of saquinavir in the therapy of HIV infection].
    Dtsch Med Wochenschr; 1995 Dec; 120(49):1721. PubMed ID: 7497905
    [No Abstract]   [Full Text] [Related]  

  • 27. Protease inhibitor: Roche lottery deadline July 21.
    AIDS Treat News; 1995 Jul; (no 226):4-5. PubMed ID: 11362614
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lotteries set up for two experimental AIDS drugs.
    Am J Health Syst Pharm; 1995 Sep; 52(17):1848. PubMed ID: 8528844
    [No Abstract]   [Full Text] [Related]  

  • 29. Lottery opens 2,000 slots for protease trial.
    AIDS Alert; 1995 Nov; 10(11):144. PubMed ID: 11362929
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Saquinavir prolongs survival and slows disease progression.
    BETA; 1996 Jun; ():6. PubMed ID: 11363649
    [TBL] [Abstract][Full Text] [Related]  

  • 31. No tease this time--pros and cons of a long-awaited anti-HIV drug.
    Chang HE
    Posit Aware; 1996; 7(1):18-20. PubMed ID: 11363118
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Saquinavir: too early to market?
    Steele FR
    Nat Med; 1996 Mar; 2(3):257. PubMed ID: 8612212
    [No Abstract]   [Full Text] [Related]  

  • 33. [For the first time a combination of 2 protease inhibitors investigated].
    Schenk M
    Dtsch Med Wochenschr; 1996 Aug; 121(34-35):A36. PubMed ID: 8829900
    [No Abstract]   [Full Text] [Related]  

  • 34. Protease inhibitors and prevention of cross resistance.
    Levin J
    AIDS Treat News; 1995 Oct; (no 232):1-3. PubMed ID: 11362875
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Roche and Merck begin expanded access programs for protease inhibitor drugs.
    Baker R
    BETA; 1995 Sep; ():4. PubMed ID: 11362890
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Saquinavir: newest weapon in the antiviral arsenal.
    MacDougall DS
    J Int Assoc Physicians AIDS Care; 1996 Feb; 2(2):25-31. PubMed ID: 11363336
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Trial volunteers sought.
    Meyer C
    Am J Nurs; 1993 May; 93(5):12. PubMed ID: 8488890
    [No Abstract]   [Full Text] [Related]  

  • 38. New drugs for HIV infection.
    Med Lett Drugs Ther; 1996 Apr; 38(972):35-7. PubMed ID: 8606677
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Roche investigators say Invirase does not cause cross-resistance to other protease inhibitors.
    Baker R
    BETA; 1995 Sep; ():5. PubMed ID: 11362895
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Abbott agrees to expanded access for ritonavir.
    Baker R
    BETA; 1995 Sep; ():4. PubMed ID: 11362891
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.